APRINOIA Therapeutics Inc. Launches a New Contract Service to Measure High-Molecular-Weight Oligomer Tau Species Using High-Sensitive ELISA System

APRINOIA Therapeutics Inc. Launches a New Contract Service to Measure High-Molecular-Weight Oligomer Tau Species Using High-Sensitive ELISA System Tokyo, Japan, May 7, 2025 – APRINOIA Therapeutics Inc. (“APRINOIA”), a clinical-stage biopharmaceutical company, is pleased to announce a new service for HMWoTau measurements for research institutions and companies engaged in pathophysiological research and drug/diagnostics development targeting […]

Steven Paget, Ph.D

Steven Paget, Ph.D. Director, Head of Medicinal Chemistry APRINOIA Team Leader, Venenum Biodesign Senior Researcher, Center for Emerging and Re-emerging Pathogens, Rutgers University Senior Scientist, PTC Therapeutics Senior Scientist, Johnson & Johnson Ph.D., The Ohio State University BA, Cornell University Development candidates in neurology (Tau PET tracer), immuno-oncology (STING agonist), antiviral (Hepatitis C), antimicrobial (oxazolidinone, […]

APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease

APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease Tokyo, Japan – December 10, 2024 – APRINOIA Therapeutics has developed a novel enzyme-linked immunosorbent assay (ELISA) that employs its proprietary monoclonal antibody APNmAb005, which […]

APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy

APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in the U.S.,U.K., Europe […]

APRINOIA Therapeutics Inc. receives “Study May Proceed” letter from FDA for a Phase 3 study of APN-1607 (florzolotau) for the diagnosis of Progressive Supranuclear Palsy

APRINOIA Therapeutics Inc. receives “Study May Proceed” letter from FDA for a Phase 3 study of APN-1607 (florzolotau) for the diagnosis of Progressive Supranuclear Palsy Cambridge, MA, January 3, 2024 — APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”) is pleased to announce that on December 8, 2023, the United States Food and Drug Administration (“FDA”) […]

APRINOIA Therapeutics Announces Strategic Investment From the Alzheimer’s Drug Discovery Foundation (ADDF)​

APRINOIA Therapeutics Announces Strategic Investment From the Alzheimer’s Drug Discovery Foundation (ADDF) CAMBRIDGE, Mass., September 11, 2023 — APRINOIA Therapeutics (“APRINOIA” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases, headquartered in Cambridge, MA, is pleased to announce the strategic investment by the Alzheimer’s Drug […]

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company’s clinical therapeutic and diagnostic programs August 28, 2023 11:00 ET APRINOIA Therapeutics (“APRINOIA”), a global […]

APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases

APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System (“CNS”) Diagnostics and Therapeutics, including CNS Protein Degraders Anticipated Proceeds […]